SPEECH-PROCESSING
18.11.2015 10:09:46 CET | Business Wire | Press release
Speech Processing Solutions , the worldwide leader in professional dictation has received excellent reviews for its Philips SpeechMike Premium. The proven and almost indestructible dictation microphone offers users superior audio quality, coupled with unique antimicrobial housing and excellent ergonomics. The fully customizable dictation microphone saves time, increases efficiency and ultimately lowers costs for professionals across a variety of industry sectors.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151118005582/en/
The leader in healthcare
Philips SpeechMike has become a household name in many industries, particularly in the healthcare sector where the dictation microphone seamlessly integrates into leading healthcare IT systems. “It’s been a very reliable system for us. We’ve had great long-term success (…) I would highly recommend the SpeechMike Premium to any hospital with demanding dictation needs” explains Dave Baumgardner, Director of Information Management, Union Hospital in Dover, Ohio, USA.
Philips SpeechMike: A history of innovation
Speech Processing Solutions celebrated their 60th anniversary last year, driven by setting standards in the dictation industry by successful innovations. The original Philips SpeechMike was first launched in 1996. “The current top model, Philips SpeechMike Premium, is the result of almost two decades of attention to detail and striving for excellence through listening to customer’s needs from all over the world” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions.
Made for speech recognition
Thanks to its special features such as the free floating microphone, the polished surface for non-sensitivity to touch noise, or the unique audio-optimized microphone grill, the Philips SpeechMike creates studio-like audio recordings . Together they successfully reduce unwanted surround sounds which enables two radiologists for example, to dictate simultaneously in one room without any interference. The clear recording levels enable the highest possible speech recognition accuracy. The dictation device is designed to work in perfect harmony with speech recognition software and has been awarded the highest possible Nuance speech recognition rating. This underlines Philips' position as global leader in audio competence, also underpinned by superior customer reviews.
Unlike many competitor products, the Philips SpeechMike offers exceptional features such as its antimicrobial housing, which is especially important in medical settings. The device fits perfectly into the hand where the ergonomic keyboard layout guarantees comfortable operation, even when dictating for several hours. Philips also carries out most extensive ‘stress tests’, making sure all devices are of exceptional quality, setting the benchmark in the dictation microphone industry. Dr. Thomas Brauner makes the point: “As our customers say: The best or nothing!”
For more information on the Philips SpeechMike please visit: www.philips.com/dictation
About Speech Processing Solutions
Speech Processing Solutions is the global number one in professional dictation. Founded in Austria in 1954 as part of Philips, the company has been the driving force in speech-to-text innovations for over 60 years. Always striving for excellence and putting emphasis on outstanding quality, the company has designed groundbreaking products, such as the portable Philips Pocket Memo voice recorder , the Philips SpeechMike Premium dictation microphone and the Philips SpeechExec dictation recorder app for smartphones. The latest innovation, Philips SpeechLive , makes dictation quicker and more convenient than ever before, by bringing secure dictation workflow to the cloud and enabling seamless speech-to-text with the new service Philips SpeechScribe. With solutions perfectly tailored to individual industry needs, Speech Processing Solutions has helped millions of satisfied customers around the globe save time and resources, allowing them to work as efficiently as possible.
Connect with Speech Processing Solutions on:
Facebook: http://www.facebook.com/philipsvoicetracer
Twitter @speech_com: http://www.twitter.com/speech_com
YouTube: http://www.youtube.com/philipsdictation
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
View source version on businesswire.com: http://www.businesswire.com/news/home/20151118005582/en/
./ContentItem/FormatPhilips SpeechMike Premium - the best or nothing
Contact:
Speech Processing Solutions
Richard Bancej
Richard.bancej@speech.com
Tel:
+43 1 60101-4191
www.philips.com/dictation
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
